194 related articles for article (PubMed ID: 34215305)
1. Crohn disease-like enterocolitis remission after empagliflozin treatment in a child with glycogen storage disease type Ib: a case report.
Rossi A; Miele E; Fecarotta S; Veiga-da-Cunha M; Martinelli M; Mollica C; D'Armiento M; Mozzillo E; Strisciuglio P; Derks TGJ; Staiano A; Parenti G
Ital J Pediatr; 2021 Jul; 47(1):149. PubMed ID: 34215305
[TBL] [Abstract][Full Text] [Related]
2. Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor.
Wortmann SB; Van Hove JLK; Derks TGJ; Chevalier N; Knight V; Koller A; Oussoren E; Mayr JA; van Spronsen FJ; Lagler FB; Gaughan S; Van Schaftingen E; Veiga-da-Cunha M
Blood; 2020 Aug; 136(9):1033-1043. PubMed ID: 32294159
[TBL] [Abstract][Full Text] [Related]
3. Empagliflozin for treating neutropenia and neutrophil dysfunction in 21 infants with glycogen storage disease 1b.
Grünert SC; Gautschi M; Baker J; Boyer M; Burlina A; Casswall T; Corpeleijn W; Çıki K; Cotter M; Crushell E; Derks TGJ; Haas D; Kilavuz S; Kingma SDK; Korman SH; Kozek A; de Laet C; Mundy H; Nassogne MC; Quintero V; Rossi A; Spenger J; Spiegel R; Stephenne X; Stojkov D; Tal G; Veiga-da Cunha M; Wortmann SB
Mol Genet Metab; 2024 Jun; 142(2):108486. PubMed ID: 38733639
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of empagliflozin in glycogen storage disease type Ib: Data from an international questionnaire.
Grünert SC; Derks TGJ; Adrian K; Al-Thihli K; Ballhausen D; Bidiuk J; Bordugo A; Boyer M; Bratkovic D; Brunner-Krainz M; Burlina A; Chakrapani A; Corpeleijn W; Cozens A; Dawson C; Dhamko H; Milosevic MD; Eiroa H; Finezilber Y; Moura de Souza CF; Garcia-Jiménez MC; Gasperini S; Haas D; Häberle J; Halligan R; Fung LH; Hörbe-Blindt A; Horka LM; Huemer M; Uçar SK; Kecman B; Kilavuz S; Kriván G; Lindner M; Lüsebrink N; Makrilakis K; Mei-Kwun Kwok A; Maier EM; Maiorana A; McCandless SE; Mitchell JJ; Mizumoto H; Mundy H; Ochoa C; Pierce K; Fraile PQ; Regier D; Rossi A; Santer R; Schuman HC; Sobieraj P; Spenger J; Spiegel R; Stepien KM; Tal G; Tanšek MZ; Torkar AD; Tchan M; Thyagu S; Schrier Vergano SA; Vucko E; Weinhold N; Zsidegh P; Wortmann SB
Genet Med; 2022 Aug; 24(8):1781-1788. PubMed ID: 35503103
[TBL] [Abstract][Full Text] [Related]
5. Clinical spectrum, over 12-year follow-up and experience of SGLT2 inhibitors treatment on patients with glycogen storage disease type Ib: a single-center retrospective study.
Shao YX; Liang CL; Su YY; Lin YT; Lu ZK; Lin RZ; Zhou ZZ; Zeng CH; Tao CY; Liu ZC; Zhang W; Liu L
Orphanet J Rare Dis; 2024 Apr; 19(1):155. PubMed ID: 38605407
[TBL] [Abstract][Full Text] [Related]
6. Improved inflammatory bowel disease, wound healing and normal oxidative burst under treatment with empagliflozin in glycogen storage disease type Ib.
Grünert SC; Elling R; Maag B; Wortmann SB; Derks TGJ; Hannibal L; Schumann A; Rosenbaum-Fabian S; Spiekerkoetter U
Orphanet J Rare Dis; 2020 Aug; 15(1):218. PubMed ID: 32838757
[TBL] [Abstract][Full Text] [Related]
7. Treatment recommendations for glycogen storage disease type IB- associated neutropenia and neutrophil dysfunction with empagliflozin: Consensus from an international workshop.
Grünert SC; Derks TGJ; Mundy H; Dalton RN; Donadieu J; Hofbauer P; Jones N; Uçar SK; LaFreniere J; Contreras EL; Pendyal S; Rossi A; Schneider B; Spiegel R; Stepien KM; Wesol-Kucharska D; Veiga-da-Cunha M; Wortmann SB
Mol Genet Metab; 2024 Mar; 141(3):108144. PubMed ID: 38277989
[TBL] [Abstract][Full Text] [Related]
8. Understanding the role of SGLT2 inhibitors in glycogen storage disease type Ib: the experience of one UK centre.
Halligan RK; Dalton RN; Turner C; Lewis KA; Mundy HR
Orphanet J Rare Dis; 2022 May; 17(1):195. PubMed ID: 35549996
[TBL] [Abstract][Full Text] [Related]
9. Crohn-like disease long remission in a pediatric patient with glycogen storage disease type Ib treated with empagliflozin: a case report.
Calia M; Arosio AML; Crescitelli V; Fornari A; Pretese R; Gasperini S; Zuin G
Therap Adv Gastroenterol; 2023; 16():17562848231202138. PubMed ID: 37779861
[TBL] [Abstract][Full Text] [Related]
10. Neutrophil functions in patients with neutropenia due to glycogen storage disease type 1b treated with empagliflozin.
Kaczor M; Malicki S; Folkert J; Dobosz E; Bryzek D; Chruscicka-Smaga B; Greczan M; Wesół-Kucharska D; Piątosa B; Samborowska E; Madzio J; Książyk J; Ehmke Vel Emczyńska E; Hajdacka M; Potempa J; Młynarski W; Rokicki D; Veillard F
Blood Adv; 2024 Jun; 8(11):2790-2802. PubMed ID: 38531056
[TBL] [Abstract][Full Text] [Related]
11. Empagliflozin in children with glycogen storage disease-associated inflammatory bowel disease: a prospective, single-arm, open-label clinical trial.
Li Z; Zhang X; Chen H; Zeng H; Wu J; Wang Y; Ma N; Lan J; Zhang Y; Niu H; Shang L; Jiang X; Yang M
Sci Rep; 2024 Apr; 14(1):8630. PubMed ID: 38622211
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the diagnosis, treatment, and follow-up of a group of Turkish pediatric glycogen storage disease type 1b patients with varying clinical presentations and a novel mutation.
Küçükçongar Yavaş A; Engin Erdal A; Bilginer Gürbüz B; Ünlüsoy Aksu A; Kasapkara ÇS
J Pediatr Endocrinol Metab; 2023 Nov; 36(11):1092-1099. PubMed ID: 37791580
[TBL] [Abstract][Full Text] [Related]
13. Untargeted metabolomic profiling in a patient with glycogen storage disease Ib receiving empagliflozin treatment.
Tallis E; Karsenty CL; Grimes AB; Karam LB; Elsea SH; Sutton VR; Rawls-Castillo BL; Liu N; Soler-Alfonso C
JIMD Rep; 2022 Jul; 63(4):309-315. PubMed ID: 35822097
[TBL] [Abstract][Full Text] [Related]
14. Antibodies to CBir1 are associated with glycogen storage disease type Ib.
Davis MK; Valentine JF; Weinstein DA; Polyak S
J Pediatr Gastroenterol Nutr; 2010 Jul; 51(1):14-8. PubMed ID: 20410847
[TBL] [Abstract][Full Text] [Related]
15. Current understanding on pathogenesis and effective treatment of glycogen storage disease type Ib with empagliflozin: new insights coming from diabetes for its potential implications in other metabolic disorders.
Maiorana A; Tagliaferri F; Dionisi-Vici C
Front Endocrinol (Lausanne); 2023; 14():1145111. PubMed ID: 37152929
[TBL] [Abstract][Full Text] [Related]
16. Neutropenia in glycogen storage disease Ib: outcomes for patients treated with granulocyte colony-stimulating factor.
Dale DC; Bolyard AA; Marrero T; Kelley ML; Makaryan V; Tran E; Leung J; Boxer LA; Kishnani PS; Austin S; Wanner C; Ferrecchia IA; Khalaf D; Maze D; Kurtzberg J; Zeidler C; Welte K; Weinstein DA
Curr Opin Hematol; 2019 Jan; 26(1):16-21. PubMed ID: 30451720
[TBL] [Abstract][Full Text] [Related]
17. Dapagliflozin and Empagliflozin in Paediatric Indications: A Systematic Review.
Lava SAG; Laurence C; Di Deo A; Sekarski N; Burch M; Della Pasqua O
Paediatr Drugs; 2024 May; 26(3):229-243. PubMed ID: 38635113
[TBL] [Abstract][Full Text] [Related]
18. Repurposing of Empagliflozin as a Possible Treatment for Neutropenia and Inflammatory Bowel Disease in Glycogen Storage Disease Type Ib: A Case Report.
Makrilakis K; Barmpagianni A; Veiga-da-Cunha M
Cureus; 2022 Jul; 14(7):e27264. PubMed ID: 36039216
[TBL] [Abstract][Full Text] [Related]
19. Empagliflozin ameliorated neutropenia in a girl with glycogen storage disease Ib.
Mikami M; Arai A; Mizumoto H
Pediatr Int; 2021 Nov; 63(11):1394-1396. PubMed ID: 34378838
[No Abstract] [Full Text] [Related]
20. Long term G-CSF-induced remission of ulcerative colitis-like inflammatory bowel disease in a patient with glycogen storage disease Ib and evaluation of associated neutrophil function.
Alsultan A; Sokol RJ; Lovell MA; Thurman G; Ambruso DR
Pediatr Blood Cancer; 2010 Dec; 55(7):1410-3. PubMed ID: 20830779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
